Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models

Pharmacology

Volumn 88, Issue 1-2, 2011, Pages 100-113

  Tung, David ^a   Cheung, Peter H ^a   Kaur, Pali ^b   Foreman, Oded ^b   Kavirayani, Anoop ^b   Hain, Heather S ^c   Saha, Saurabh ^a  

^a BioMed Valley Discoveries   (United States)

^b JACKSON LABORATORY   (United States)

^c Melior Discovery Inc   (United States)

Author keywords

Bortezomib; Delayed type hypersensitivity model; Imiquimod induced psoriasis model; Immune modulation; Inflammation; Psoriasis; Topical formulation; Velcade

Indexed keywords

BORTEZOMIB; CLOBETASOL; CYTOKINE; HYDROCORTISONE; HYDROXYPROPYLCELLULOSE; IMIQUIMOD; MONOCYTE CHEMOTACTIC PROTEIN 1; PROPYLENE GLYCOL;

ACANTHOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG POTENTIATION; DRUG STABILITY; DRUG TOLERABILITY; EAR SWELLING; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERKERATOSIS; IMMUNOMODULATION; INFLAMMATORY INFILTRATE; MALE; MOUSE; NONHUMAN; PARAKERATOSIS; PERITONITIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; SKIN DEFECT; SKIN NECROSIS; SKINFOLD; SWELLING;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BORONIC ACIDS; DINITROFLUOROBENZENE; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC FACTORS; IRRITANTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; PERITONITIS; PSORIASIS; PYRAZINES; RANDOM ALLOCATION; TEMPERATURE; THIOGLYCOLATES;

EID: 80051915832     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000330067     Document Type: Article

References (58)

1. Gallastegui N, Groll M: The 26S proteasome: Assembly and function of a destructive machine. Trends Biochem Sci 2010; 35: 634-642.
2. Gyrd-Hansen M, Meier P: IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation cancer. Nat Rev Cancer 2010; 10: 561-574.
3. Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1:a001651.
4. Mantovani A: Molecular pathways linking inflammation and cancer. Curr Mol Med 2010; 10: 369-373.
5. Muller-Ladner U, Gay RE, Gay S: Role of nuclear factor kappaB in synovial inflammation. Curr Rheumatol Rep 2002; 4: 201-207.
6. Sanz AB, Sanchez-Nino MD, Ramos AM, Moreno JA, Santamaria B, Ruiz-Ortega M, et al: NF-kappaB in renal inflammation. J Am Soc Nephrol 2010; 21: 1254-1262.
7. Tak PP, Firestein GS: NF-kappaB: A key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11. (Pubitemid 32047405)
8. Colmegna I, Sainz B Jr, Garry RF, Espinoza LR: The proteasome and its implications in rheumatology. J Rheumatol 2005; 32: 1192-1198. (Pubitemid 40995369)
9. Rock KL, Goldberg AL: Degradation of cell proteins and the generation of MHC class Ipresented peptides. Annu Rev Immunol 1999; 17: 739-779. (Pubitemid 29241139)
10. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al: Inhibitors of the proteasome block the degradation of most cell generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761-771. (Pubitemid 24294452)
11. Goldberg AL, Cascio P, Saric T, Rock KL: The importance of the proteasome and subsequent proteolytic steps in generation of antigenic peptides. Mol Immunol 2002; 39: 147-164. (Pubitemid 35013508)
12. Oh SY, Park JU, Zheng T, Kim YK, Wu F, Cho SH, et al: Cbl-b regulates airway mucosal tolerance to aeroallergen. Clin Exp Allergy 2010; 41: 434-442.
13. Zhang J, Bardos T, Li D, Gal I, Vermes C, Xu J, et al: Cutting edge: Regulation of T cell activation threshold by CD28 through targeting Cbl-b for ubiquitination. J Immunol 2002; 169: 2236-2240. (Pubitemid 34920962)
14. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al: Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-15676. (Pubitemid 29018758)
15. Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, Driessen C, et al: Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 2008; 38: 2401-2411.
16. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, et al: Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120-8125. (Pubitemid 38698064)
17. Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR, et al: Differential effects of proteasome inhibition by bortezomib on murine graft-versus-host disease (GVHD): Delayed administration of bortezomib increased GVHD-dependent gastrointestinal toxicity. Blood 2005; 106: 3293-3299. (Pubitemid 41565932)
18. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR: NF-kappaB as a target for the prevention of graft-versus-host disease: Comparative efficacy of bortezomib and PS-1145. Blood 2006; 107: 827-834. (Pubitemid 43076412)
19. Zweegman S, Janssen JJ, Lokhorst HM: Immune-modulatory effects of bortezomib in GVHD. Leuk Lymphoma 2007; 48: 853-854. (Pubitemid 47161554)
20. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, et al: Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575-3583.
21. Mak RK, Hundhausen C, Nestle FO: Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr 2009; 100(suppl 2):2-13.
22. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH: Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 2002; 109: 671-679. (Pubitemid 34204846)
23. Mateos MV: Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010; 36(suppl 2):S24-S32.
24. Takahashi M, Galligan C, Tessarollo L, Yoshimura T: Monocyte chemoattractant protein-1 (MCP-1), not MCP-3, is the primary chemokine required for monocyte recruitment in mouse peritonitis induced with thioglycollate or zymosan A. J Immunol 2009; 183: 3463-3471.
25. Schwarz A, Grabbe S, Riemann H, Aragane Y, Simon M, Manon S, et al: In vivo effects of interleukin-10 on contact hypersensitivity and delayed-type hypersensitivity reactions. J Invest Dermatol 1994; 103: 211-216. (Pubitemid 24234610)
26. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182: 5836-5845.
27. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ: Purification and characterization of a novel monocyte chemotactic and factor produced by a human myelomonocytic cell line. J Exp Med 1989; 169: 1485-1490. (Pubitemid 19104979)
28. Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ: Human monocyte chemoattractant protein-1 (MCP-1). Fulllength cDNA expression in mitogen-stimulated blood mononuclear leukocytes, and similarity to mouse competence gene JE. FEBS Lett 1989; 244: 487-493. (Pubitemid 19067175)
29. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE: Regulation of protein function by glycosaminoglycans -as exemplified by chemokines. Annu Rev Biochem 2005; 74: 385-410. (Pubitemid 40995512)
30. Luster AD: Chemokines -chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445. (Pubitemid 28135672)
31. Proudfoot AE: Chemokine receptors: Multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-115. (Pubitemid 37323234)
32. Rollins BJ: Monocyte chemoattractant protein 1: A potential regulator of monocyte in inflammatory disease. Mol Med Today 1996; 2: 198-204. (Pubitemid 126401890)
33. Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol. 2001; 2: 108-115. (Pubitemid 33707927)
34. Handel TM, Johnson Z, Rodrigues DH, Dos Santos AC, Cirillo R, Muzio V, et al: An engineered monomer of CCL2 has anti-inflammatory properties importance of oligomerization for chemokine activity in vivo. J Leukoc Biol 2008; 84: 1101-1108.
35. Takahashi M, Galligan C, Tessarollo L, Yoshimura T: Monocyte chemoattractant protein-1 (MCP-1), not MCP-3, is the primary required for monocyte recruitment in mouse peritonitis induced with thioglycollate or zymosan A. J Immunol 2009; 183: 3463-3471.
36. Nagai H, Ueda Y, Ochi T, Hirano Y, Tanaka H, Inagaki N, et al: Different role of IL-4 in the onset of hapten-induced contact BALB/c and C57BL/6 mice. Br J Pharmacol 2000; 129: 299-306. (Pubitemid 30072650)
37. Nagai H, Hiyama H, Matsuo A, Ueda Y, Inagaki N, Kawada K: FK-506 and cyclosporin A potentiate the IgE antibody production by sensitization with hapten in mice. J Pharmacol Exp Ther 1997; 283: 321-327. (Pubitemid 27438977)
38. Nagai H, Matsuo A, Hiyama H, Inagaki N, Kawada K: Immunoglobulin E production in mice by means of contact sensitization simple chemical, hapten. J Allergy Clin Immunol 1997; 100:S39-S44.
39. Abe M, Kondo T, Xu H, Fairchild RL: Interferon-gamma inducible protein (IP-10) expression is mediated by and is regulated by CD4+ T cells during the elicitation of contact hypersensitivity. J Invest Dermatol 1996; 107: 360-366. (Pubitemid 26284344)
40. Riemann H, Schwarz A, Grabbe S, Aragane Y, Luger TA, Wysocka M, et al: Neutralization of IL-12 in vivo prevents induction of contact and induces hapten-specific tolerance. J Immunol 1996; 156: 1799-1803. (Pubitemid 26069312)
41. Xu B, Aoyama K, Kitani A, Yu S, Matsuyama T, Matsushita T: Interleukin-12 enhances contact hypersensitivity by modulating the in cytokine pattern in mice. J Interferon Cytokine Res 1998; 18: 23-31. (Pubitemid 28084073)
42. Xu H, DiIulio NA, Fairchild RL: T cell populations primed by hapten sensitization in contact distinguished by polarized patterns of cytokine production: Interferon gammaproducing (Tc1) effector CD8+ T cells and interleukin (Il) 4/Il-10-producing (Th2) negative regulatory CD4+ T cells. J Exp Med 1996; 183: 1001-1012.
43. Egerer K, Kuckelkorn U, Rudolph PE, Ruckert JC, Dorner T, Burmester GR, et al: Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 2002; 29: 2045-2052.
44. Mountz JD: Significance of increased circulating proteasome in autoimmune disease. J Rheumatol 2002; 29: 2027-2030.
45. Qureshi N, Vogel SN, Van Way C, 3rd, Papasian CJ, Qureshi AA, Morrison DC: The proteasome: A central regulator of inflammation and macrophage. Immunol Res 2005; 31: 243-260. (Pubitemid 40628961)
46. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA: Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994; 91: 3652-3666.
47. Xu LL, Warren MK, Rose WL, Gong W, Wang JM: Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol 1996; 60: 365-371. (Pubitemid 26325618)
48. Conti P, Pang X, Boucher W, Letourneau R, Reale M, Barbacane RC, et al: Monocyte chemotactic protein-1 is a proinflammatory chemokine in rat skin injection sites and chemoattracts basophilic granular cells. Int Immunol 1997; 9: 1563-1570. (Pubitemid 27434689)
49. Conti P, Boucher W, Letourneau R, Feliciani C, Reale M, Barbacane RC, et al: Monocyte chemotactic protein-1 provokes mast cell aggregation and [3H]5HT release. Immunology 1995; 86: 434-440.
50. Bischoff SC, Krieger M, Brunner T, Dahinden CA: Monocyte chemotactic protein 1 is a potent activator of human basophils. J Exp Med 1992; 175: 1271-1275.
51. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in antiinflammatory activity. Proc Natl Acad Sci USA 1999; 96: 10403-10408. (Pubitemid 29422570)
52. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, et al: The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. J Leukoc Biol 2010; 88: 117-122.
53. Schoenborn JR, Wilson CB: Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 2007; 96: 41-101. (Pubitemid 350018717)
54. Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-189. (Pubitemid 38174573)
55. Kalinski P, Hilkens CM, Snijders A, Snijdewint FG, Kapsenberg ML: IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997; 159: 28-35. (Pubitemid 127493681)
56. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419-1428. (Pubitemid 32708698)
57. Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, et al: Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther 2008; 7: 1949-1960.
58. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C: Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 2008; 103: 270-283.